VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Millennium Pharmaceuticals, Inc.
Study ID
NCT00085696
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.

Key Dates

Start date
May 31, 2004
Status verified
Feb 2008
Primary completion
Apr 30, 2006

Study Design

Enrollment
66 participants
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Locations (13)

FacilityCityStateZIPSite coordinators
UCLA School of MedicineLos AngelesCalifornia90095-
Florida Cancer SpecialistsFort MyersFlorida33901-
Emory University Cancer Institute, Winship Cancer InstituteAtlantaGeorgia30322-
Georgia Cancer SpecialistsMariettaGeorgia30060-
Rush University Medical CenterChicagoIllinois60612-
Midwest Cancer Research GroupSkokieIllinois60077-
Cancer Center of KansasWichitaKansas67214-
Oncology/Henmatology Associates of Kansas CityKansas CityMissouri64111-
Mid Ohio Oncology/Hematology Inc.ColumbusOhio43213-
Charleston Cancer CenterCharlestonSouth Carolina29406-
MD Anderson Cancer CenterHoustonTexas77030-
University of Utah, Huntsman Cancer InstituteSalt Lake CityUtah84112-
FNVHO - US OncologyFairfaxVirginia20031-

Find similar trials in Los Angeles, CA

By research site
UCLA School of Medicine· Los Angeles, CAFlorida Cancer Specialists· Fort Myers, FLEmory University Cancer Institute, Winship Cancer Institute· Atlanta, GAGeorgia Cancer Specialists· Marietta, GARush University Medical Center· Chicago, ILMidwest Cancer Research Group· Skokie, IL

Related Studies